Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells

Molecular and Cellular Endocrinology

Volumn 150, Issue 1-2, 1999, Pages 11-21

  Castro Rivera, Emely ^a   Wormke, Mark ^a   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Ah receptor; Antiestrogen; ECC 1; Endometrial cells; Estrogen

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; AROMATIC HYDROCARBON; AROMATIC HYDROCARBON RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BREAST CELL; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; TRANSACTIVATION;

CATHEPSIN D; CELL DIVISION; ENDOMETRIAL NEOPLASMS; ENVIRONMENTAL POLLUTANTS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; RECEPTOR CROSS-TALK; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TETRACHLORODIBENZODIOXIN; TUMOR CELLS, CULTURED;

EID: 0033602654     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00041-6     Document Type: Article

References (68)

1. Anzai Y., Holinka C.F., Kuramoto H., Gurpide E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res. 49:1989;2362-2365.
2. Astroff B., Safe S. Comparative antiestrogenic activities of 2,3,7,8- tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8- trichlorodibenzofuran in the female rat. Toxicol. Appl. Pharmacol. 95:1988;435-443.
3. Baron J.A., Byers T., Greenberg E.R., Cummings K.M., Swanson M. Cigarette smoking in women with cancers of the breast and reproductive organs. J. Natl. Cancer Inst. 77:1986;677-680.
4. Baron J.A., La Vecchia C., Levi F. The antiestrogenic effect of cigarette smoking in women. Am. J. Obstet. Gynecol. 162:1990;502-514.
5. Baron J.A. Beneficial effects of nicotine and cigarette smoking - the real, the possible and the spurious. Br. Med. Bull. 52:1996;58-73.
6. Bennicke K., Conrad C., Sabroe S., Sorensen H.T. Cigarette smoking and breast cancer. Br. Med. J. 310:1995;1431-1433.
7. Castro-Rivera E., Safe S. Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture. J. Steroid Biochem. Mol. Biol. 64:1998;287-295.
8. Cavailles V., Augereau P., Garcia M., Rochefort H. Estrogens and growth factors induce mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Res. 16:1988;1903-1919.
9. Chaloupka K., Krishnan V., Safe S. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in MCF-7 human breast cancer cells. Role of the Ah receptor. Carcinogenesis. 13:1992;2223-2239.
10. Chen I., McDougal A., Wang F., Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis. 19:1998;1631-1639.
11. Clarke C.L., Satyaswaroop P.G. Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res. 45:1985;5417-5420.
12. Cook L.S., Weiss N.S., Schwartz S.M., White E., McKnight B., Moore D.E., Daling J.R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. Natl. Cancer Inst. 87:1995;1359-1364.
13. Curtis R.E., Boice J.D. Jr., Shriner D.A., Hankey B.F., Fraumeni J.F. Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88:1996;832-834.
14. Dickerson R., Howie-Keller L., Safe S. Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. Toxicol. Appl. Pharmacol. 135:1995;287-298.
15. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
16. Furr B.J., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Therap. 25:1984;127-205.
17. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
18. Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.C. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 50:1990;3189-3192.
19. Harper N., Wang X., Liu H., Safe S. Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol. Cell. Endocrinol. 104:1994;47-55.
20. Harris M., Piskorska-Pliszczynska J., Zacharewski T., Romkes M., Safe S. Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor. Cancer Res. 49:1989;4531-4535.
21. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48:1988;246-253.
22. Hobson G.M., Molloy G.R., Benfield P.A. Identification of cis-acting regulatory elements in the promoter region of the rat brain creatine kinase gene. Mol. Cell. Biol. 10:1990;6533-6543.
23. Holinka C.F., Anzai Y., Hata H., Kimmel N., Kuramoto H., Gurpide E. Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions. Cancer Res. 49:1989;3297-3301.
24. Horwitz K.B. When tamoxifen turns bad. Endocrinology. 136:1995;821-823.
25. Hulka B.S., Liu E.T., Lininger R.A. Steroid hormones and risk of breast cancer. Cancer. 74:1994;1111-1124.
26. Jamil A., Croxtall J.D., White J.O. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. Mol. Endocrinol. 6:1991;215-221.
27. Jordan V.C., Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur. J. Cancer. 30A:1994;1714-1721.
28. Jordan V.C., Murphy C.S. Endocrine pharmacology of antiestrogens. Endocrine Rev. 11:1990;578-610.
29. Jordan V.C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat. 31:1994;41-52.
30. Jordan V.C. Tamoxifen and tumorigenicity: a predictable concern. J. Natl. Cancer Inst. 87:1995;623-625.
31. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology-interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:1996;119-131.
32. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 343:1994;1318-1321.
33. Key T.J.A., Pike M.C. The dose-effect relationship between'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer. 57:1988;205-212.
34. King C.M. Tamoxifen and the induction of cancer. Carcinogenesis. 16:1995;1449-1454.
35. Krishnan V., Safe S. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol. Appl. Pharmacol. 120:1993;55-61.
36. Krishnan V., Wang X., Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 269:1994;15912-15917.
37. Krishnan V., Porter W., Santostefano M., Wang X., Safe S. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell. Biol. 15:1995;6710-6719.
38. Kvale G., Heuch I., Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res. 48:1988;6217-6221.
39. Lawrence C., Tessaro I., Durgerian S., Caputo T., Richart R., Jacobson H., Greenwald P. Smoking, body weight, and early-stage endometrial cancer. Cancer. 59:1987;1665-1669.
40. Lesko S.M., Rosenberg L., Kaufman D.W., Helmrich S.P., Miller D.R., Strom B., Schottenfeld D., Rosenschein N.B., Knapp R.C., Lewis J., Shapiro S. Cigarette smoking and the risk of endometrial cancer. New Engl. J. Med. 313:1985;593-596.
41. Levi F., La Vecchia C., Decarli A. Cigarette smoking and the risk of endometrial cancer. Eur. J. Cancer Clin. Oncol. 23:1987;1025-1029.
42. Liu H., Wormke M., Safe S., Bjeldanes L.F. Indolo[3,2-b]carbazole: a dietary factor which exhibits both antiestrogenic and estrogenic activity. J. Natl. Cancer Inst. 86:1994;1758-1765.
43. Martin P.M., Rolland P.H., Gammerre M., Serment H., Toga M. Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int. J. Cancer. 23:1979;321-329.
44. McDonnell D.P., Clemm D.L., Hermann T., Goldman M.E., Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:1995;659-669.
45. McDougal A., Wilson C., Safe S. Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett. 120:1997;53-63.
46. Miralles F., Gaudelet C., Cavailles V., Rochefort H., Augereau P. Insensitivity of cathepsin D gene to estradiol in endometrial cells is determined by the sequence of its estrogen responsive element. Biochem. Biophys. Res. Commun. 203:1994;711-718.
47. Nebert D.W. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. C.R.C. Crit. Rev. Toxicol. 20:1989;153-174.
48. Nguyen H.N., Sevin B.U., Averette H.E., Voigt W., Perras J., Angioli R., Ramos R., Donato D., Penalver M. Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry. Gynecol. Oncol. 46:1992;55-61.
49. Parazzini F., La Vecchia C., Bocciolone L., Franceschi S. The epidemiology of endometrial cancer. Gynecol. Oncol. 41:1991;1-16.
50. Parazzini F., La Vecchia C., Negri E., Fedele L., Balotta F. Reproductive factors and risk of endometrial cancer. Am. J. Obstet. Gynecol. 164:1991;522-527.
51. Quinn M.A., Cauchi M., Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol. Oncol. 21:1985;314-319.
52. Redecker B., Heckendorf B., Grosch H.-W., Mersmann G., Hasilik A. Molecular organization of the human cathepsin D gene. DNA Cell Biol. 10:1991;423-431.
53. Richardson G.S., MacLaughlin D.T. The status of receptors in the management of endometrial cancer. Clin. Obstet. Gynecol. 29:1986;628-637.
54. Safe S. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Therap. 67:1995;247-281.
55. Safe S. Interactions between hormone and chemicals in breast cancer. Annu. Rev. Pharmacol. Toxicol. 38:1998;121-158.
56. Satyaswaroop P.G., Tabibzadeh S.S. Extracellular matrix and the patterns of differentiation of human endometrial carcinomas in vitro and in vivo. Cancer Res. 51:1991;5661-5666.
57. Satyaswaroop P.G., Zaino R.J., Mortel R. Human endometrial adenocarcinoma transplanted into nude mice: growth regulation by estradiol. Science. 219:1983;58-60.
58. Satyaswaroop P.G., Zaino R.J., Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 44:1984;4006-4010.
59. Satyaswaroop P.G., Clarke C.L., Zaino R.J., Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett. 62:1992;107-114.
60. Smith D.C., Prentice R., Thompson D.J., Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. New Engl. J. Med. 293:1975;1164-1167.
61. Sömjen D., Waisman A., Kaye A.M. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 59:1996;389-396.
62. Touitou I., Cavailles V., Garcia M., DeFrenne A., Rochefort H. Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Mol. Cell Endocrinol. 66:1989;231-238.
63. Tyler C.W., Webster L.A. Jr., Ory H.W., Rubin G.L. Endometrial cancer: how does cigarette smoking influence the risk of women under age 55 years having this tumor? Am. J. Obstet. Gynecol. 151:1985;899-905.
64. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.G., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
65. Van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere C.H., Otter R., Schouten L.J., Damhuis R.A., Bontenbal M., Diepenhorst F.W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
66. Watanabe T., Inoue S., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A., Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β Biochem. Biophys. Res. Commun. 236:1997;140-145.
67. Westley B.R., May F.E.B. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleic Acids Res. 15:1987;3773-3780.
68. Zacharewski T., Harris M., Biegel L., Morrison V., Merchant M., Safe S. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. Toxicol. Appl. Pharmacol. 13:1992;311-318.